Lower gut abundance of

Emerging preclinical and clinical studies suggest that altered gut microbiome composition and functions are associated with coronavirus 2019 (COVID- 19) severity and its long-term complications. We hypothesize that COVID-19 outcome is associated with gut microbiome status in population-based settings. Gut metagenomic data of the adult population consisting of 2871 subjects from 16 countries were obtained from ExperimentHub through R, while the dynamic death data of COVID-19 patients between January 22, 2020 and December 8, 2020 in each country was acquired from Johns Hopkins Coronavirus Resource Center. An adjusted stable mortality rate (SMR) was used to represent these countries' mortality and correlated with the mean relative abundance (mRA) of healthy adult gut microbiome species. After excluding bacterial species with low prevalence (prevalence <0.2 in the included countries), the β-diversity was significantly higher in the countries with high SMR when compared with those with median or low SMR (p <0.001). We then identified the mRA of two butyrate producers, Population-based microbiome signatures with the stable mortality rate of COVID-19 in different countries suggest that altered gut microbiome composition and functions are associated with mortality of COVID-19.

Informations de copyright

Copyright © 2023 Liu, Chan, Chan, Wu, Ng and Zhang.

Déclaration de conflit d'intérêts

FC is Board Member of CUHK Medical Centre. He is a co-founder, non-executive Board Chairman and non-executive scientific advisor, Chief Medical Officer and shareholder of GenieBiome Ltd. shareholder of GenieBiome Ltd. He receives patent royalties through his affiliated institutions. He has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda China Holdings Co. Ltd. SN has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. SN has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie. SN is a founder member, non-executive director, non-executive scientific advisor, and shareholder of GenieBiome Ltd. SN is a scientific co-founder and shareholder of GenieBiome Ltd. SN receives patent royalties through her affiliated institutions. FC, SN and LZ are named inventors of patent applications held by the CUHK and MagIC that cover the therapeutic and diagnostic use of microbiome. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.